Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$3.38 USD

3.38
1,321,997

+0.17 (5.30%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.40 +0.02 (0.59%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

by Zacks Equity Research

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lumos (LUMO) delivered earnings and revenue surprises of 20.54% and 126.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -5.88% and 78.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights include Las Vegas Sands, Voyager Therapeutics and nCino

by Zacks Equity Research

Las Vegas Sands, Voyager Therapeutics and nCino are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Best Stocks to Invest in for Remarkable Earnings Acceleration

by Tirthankar Chakraborty

Some of the notable companies to have witnessed solid earnings acceleration as of now are Las Vegas Sands (LVS), Voyager Therapeutics (VYGR) & nCino (NCNO).

Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Voyager Therapeutics (VYGR)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alnylam (ALNY) Soars 3.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.15% and 5.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

Zacks Equity Research

FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues in the first quarter.

Zacks Equity Research

Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.

Zacks Equity Research

Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?